Modulation of inhibition of return by the dopamine D2 receptor agonist bromocriptine depends on individual DAT1 genotype

Involuntary visual spatial attention is captured when a salient cue appears in the visual field. If a target appears soon after the cue, response times to targets at the cue location are faster relative to other locations. However, after longer cue-target intervals, responses to targets at the cue l...

Full description

Saved in:
Bibliographic Details
Published in:Cerebral cortex (New York, N.Y. 1991) N.Y. 1991), 2012-05, Vol.22 (5), p.1133-1138
Main Authors: Rokem, Ariel, Landau, Ayelet N, Prinzmetal, William, Wallace, Deanna L, Silver, Michael A, D'Esposito, Mark
Format: Article
Language:English
Subjects:
Attention - drug effects
Attention - physiology
Bromocriptine - pharmacology
Corpus Striatum - metabolism
Cross-Over Studies
Dopamine - metabolism
Dopamine Agonists - pharmacology
Dopamine Plasma Membrane Transport Proteins - genetics
Double-Blind Method
Female
Genotype
Humans
Male
Neural Inhibition - drug effects
Neural Inhibition - genetics
Reaction Time - physiology
Receptors, Dopamine D2 - agonists
Visual Perception - drug effects
Visual Perception - physiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Involuntary visual spatial attention is captured when a salient cue appears in the visual field. If a target appears soon after the cue, response times to targets at the cue location are faster relative to other locations. However, after longer cue-target intervals, responses to targets at the cue location are slower, due to inhibition of return (IOR). IOR depends on striatal dopamine (DA) levels: It varies with different alleles of the DA transporter gene DAT1 and is reduced in patients with Parkinson's disease, a disease characterized by reduced striatal dopaminergic transmission. We examined the role of DA in involuntary attention and IOR by administering the DA D2 receptor-specific agonist bromocriptine to healthy human subjects. There was no effect of either DAT1 genotype or bromocriptine on involuntary attention, but participants with DAT1 alleles predicting higher striatal DA had a larger IOR. Furthermore, bromocriptine increased the magnitude of IOR in participants with low striatal DA but abolished the IOR in subjects with high striatal DA. This inverted U-shaped pattern resembles previously described relationships between DA levels and performance on cognitive tasks and suggests an involvement of striatal DA in IOR that does not include a role in involuntary attention.
ISSN:1047-3211
1460-2199
DOI:10.1093/cercor/bhr185